Patent controversies and court cases

References

• Chakrabarty AM. Bioengineered bugs, drugs and contentious issues in patenting. Bioeng Bugs 2010; 1:2 - 8; http://dx.doi.org/10.4161/bbug.1.1.9850; PMID: 21327122
   PubMedGoogle Scholar
• Fialho AM, Chakrabarty AM. The role and importance of intellectual property generation and protection in drug development. In Fialho AM, Chakrabarty AM, eds. Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools, Nutley: John Wiley & Sons, 2010: 405-19.
   Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609 - 15; http://dx.doi.org/10.1038/nature10166; PMID: 21720365
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487:330 - 7; http://dx.doi.org/10.1038/nature11252; PMID: 22810696
   PubMed Web of Science ®Google Scholar
• Fialho AM, Chakrabarty AM. Law-medicine interfacing: patenting of human genes and mutations. Recent Pat DNA Gene Seq 2011; 5:81 - 5; http://dx.doi.org/10.2174/187221511796392015; PMID: 21574951
   PubMedGoogle Scholar
• Chakrabarty AM. Bacterial proteins: A new class of cancer therapeutics. J. Commercial Biotechnol 2012; 18:4 - 10
   Google Scholar
• Das Gupta TK, Chakrabarty AM, Beattie C, Yamada T. Compositions and methods to prevent cancer with cupredoxins. US Patent 8,232,244 issued on July 31, 2012.
   Google Scholar
• Mehta RR, Hawthorne M, Peng X, Shilkaitis A, Mehta RG, Beattie CW, et al. A 28-amino-acid peptide fragment of the cupredoxin azurin prevents carcinogen-induced mouse mammary lesions. Cancer Prev Res (Phila) 2010; 3:1351 - 60; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0024; PMID: 20841487
   PubMed Web of Science ®Google Scholar
• Richards JM, Warso MA, Mehta D, Christov K, Schaeffer CM, Yamada T, et al. A first-in-class, first-in-human phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors. J Clin Oncol 2011; 29: Abstract 2511 (ASCO Annual Meeting).
   Google Scholar
• Fialho AM, Salunkhe P, Manna S, Mahali S, Chakrabarty AM. Glioblastoma multiforme: novel therapeutic approaches. ISRN Neurol 2012; 2012:642345; PMID: 22462021
   PubMedGoogle Scholar
• Avner B, Fialho AM, Chakrabarty AM. Overcoming drug resistance in multi-drug resistant cancers and microorganisms: a conceptual framework. Bioeng Bugs 2012; 3:262 - 270; PMID: 22179143
   PubMedGoogle Scholar
• Resnik DB, DeVille KA. Bioterrorism and patent rights: “compulsory licensure” and the case of Cipro. Am J Bioeth 2002; 2:29 - 39; http://dx.doi.org/10.1162/152651602760250084; PMID: 12230852
   PubMedGoogle Scholar
• Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105:3 - 7; http://dx.doi.org/10.1172/JCI9083; PMID: 10619854
   PubMed Web of Science ®Google Scholar
• Marumoto T, Tashiro A, Friedmann-Morvinski D, Scadeng M, Soda Y, Gage FH, et al. Development of a novel mouse glioma model using lentiviral vectors. Nat Med 2009; 15:110 - 6; http://dx.doi.org/10.1038/nm.1863; PMID: 19122659
   PubMed Web of Science ®Google Scholar
• Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009; 462:104 - 7; http://dx.doi.org/10.1038/nature08462; PMID: 19847165
   PubMed Web of Science ®Google Scholar
• Hollander MC, Maier CR, Hobbs EA, Ashmore AR, Linnoila RI, Dennis PA. Akt1 deletion prevents lung tumorigenesis by mutant K-ras. Oncogene 2011; 30:1812 - 21; http://dx.doi.org/10.1038/onc.2010.556; PMID: 21242979
   PubMed Web of Science ®Google Scholar
• Chaudhari A, Mahfouz M, Fialho AM, Yamada T, Granja AT, Zhu Y, et al. Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth. Biochemistry 2007; 46:1799 - 810; http://dx.doi.org/10.1021/bi061661x; PMID: 17249693
   PubMed Web of Science ®Google Scholar
• Micewicz ED, Jung C-L, Schaue D, Luong H, McBride WH, Ruchala P. Small azurin derived peptide targets ephrin receptors for radiotherapy. Int J Pept Res Ther 2011; 17:247 - 57; http://dx.doi.org/10.1007/s10989-011-9265-9
   Web of Science ®Google Scholar
• Yamada T, Goto M, Punj V, Zaborina O, Chen ML, Kimbara K, et al. Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer. Proc Natl Acad Sci U S A 2002; 99:14098 - 103; http://dx.doi.org/10.1073/pnas.222539699; PMID: 12393814
   PubMed Web of Science ®Google Scholar
• Punj V, Bhattacharyya S, Saint-Dic D, Vasu C, Cunningham EA, Graves J, et al. Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer. Oncogene 2004; 23:2367 - 78; http://dx.doi.org/10.1038/sj.onc.1207376; PMID: 14981543
   PubMed Web of Science ®Google Scholar
• Domenici F, Frasconi M, Mazzei F, D’Orazi G, Bizzarri AR, Cannistraro S. Azurin modulates the association of Mdm2 with p53: SPR evidence from interaction of the full-length proteins. J Mol Recognit 2011; 24:707 - 14; http://dx.doi.org/10.1002/jmr.1105; PMID: 21584881
   PubMedGoogle Scholar
• Mehta RR, Yamada T, Taylor BN, Christov K, King ML, Majumdar D, et al. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt. Angiogenesis 2011; 14:355 - 69; http://dx.doi.org/10.1007/s10456-011-9220-6; PMID: 21667138
   PubMed Web of Science ®Google Scholar
• Zweig FM. The limiting factor. Biotechnology and the charter for an international science and technology reference court. Not Polit 2002; 18:51 - 8; PMID: 15505917
   PubMedGoogle Scholar